<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02902536</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00078519</org_study_id>
    <nct_id>NCT02902536</nct_id>
  </id_info>
  <brief_title>Tissue Repository for Studies of Myasthenia Gravis</brief_title>
  <official_title>Tissue Repository for Studies of Myasthenia Gravis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study during which the investigators collect plasma and cells from patients with
      myasthenia gravis for the purpose of finding new antibodies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a bio-specimen collection study. The investigators will collect plasma and peripheral
      lymphocytes. Plasma will be collected either when the patient undergoes plasma exchange, a
      decision independent of this study, or through a scheduled blood draw.

      Patient plasma will be screened for novel antibodies which may cause myasthenia gravis.
      Subjects that are found to be positive for candidate antigens for myasthenia gravis will have
      a clinical evaluation which will consist of several disease rating scales will be performed
      (QMG score, MG-composite, Myasthenia Gravis Foundation of America (MGFA) clinical
      classification, MG-Quality of Life (QOL)15, MGFA Therapy Status).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of New Antibodies in Myasthenia Gravis assessed by enzyme-linked immunosorbent assay (ELISA)</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Myasthenia Gravis</condition>
  <arm_group>
    <arm_group_label>Myasthenia Positive Antibodies</arm_group_label>
    <description>Patients with Acetyl choline receptor (AChR) or muscle-specific kinase (MuSK) Positive Myasthenia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Myasthenia Double Negative</arm_group_label>
    <description>Patients without AChR or MuSK antibodies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Controls</arm_group_label>
    <description>Patients without myasthenia</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No interventions</intervention_name>
    <arm_group_label>Myasthenia Positive Antibodies</arm_group_label>
    <arm_group_label>Myasthenia Double Negative</arm_group_label>
    <arm_group_label>Normal Controls</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      We will collect patient blood.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Myasthenia Gravis and normal controls
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older.

          -  Clinical Diagnosis of MG with supporting evidence either from antibody testing,
             repetitive nerve stimulations study (RNS) or Single Fiber Electromyography (EMG)
             (SFEMG).

        Exclusion Criteria:

          -  Significant medical condition that would make participation in diagnostic and research
             part of evaluation impossible or risky. Acute or unstable medical condition.

          -  Inability to provide informed consent, either directly or via appointed power of
             attorney.

          -  Unwillingness to consent for collection of biological samples or their
             cryopreservation.

          -  Unable to provide evidence of previous antibody testing or neurophysiology confirming
             the diagnosis of Myasthenia Gravis.

          -  Any bleeding disorder that would prevent or present any danger during blood
             extraction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2016</study_first_submitted>
  <study_first_submitted_qc>September 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2016</study_first_posted>
  <last_update_submitted>March 6, 2017</last_update_submitted>
  <last_update_submitted_qc>March 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myasthenia Gravis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Weakness</mesh_term>
    <mesh_term>Myasthenia Gravis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

